Personal Injury Lawyer America.com - A newsletter from the national law firm of Lieff Cabraser Heimann & Bernstein, LLP
Home button
Find a case
About Our Firm button
Contact us
SEARCH  
shim
  RECENT CASES  
   
  Complete list of all cases  
   
  GENERAL INFORMATION  
   
  Send us an email  
     
 

September 2006 FDA Ortho Evra Contraceptive Patch Warning & Information Document Updates

Updated FDA Ortho Evra Documents:
Previous Updates
On November 10, 2005 the Food and Drug Administration isued the warning information below, prompting Ortho-McNeil Pharmeceutical Inc., the makers of the Ortho Evra patch to issue new prescribing information:
The Food and Drug Administration approved updated labeling for the Ortho Evra contraceptive patch to warn healthcare providers and patients that this product exposes women to higher levels of estrogen than most birth control pills. Ortho Evra was the first skin patch approved for birth control.
Ortho Evra is a weekly prescription patch that releases ethinyl estradiol (an estrogen hormone) and norelgestromin (a progestin hormone) through the skin into the blood stream. FDA advises women to talk to their doctor or healthcare provider about whether the patch is the right method of birth control for them.
Furthermore, women taking or considering using this product should work with their health care providers to balance the potential risks related to increased estrogen exposure against the risk of pregnancy if they do not follow the daily regimen associated with typical birth control pills. Because Ortho Evra is a patch that is changed once a week, it decreases the chance associated with typical birth control pills that a woman might miss one or more daily doses.
The addition of this new warning is a result of FDA's and the manufacturer's analysis directly comparing the levels for estrogen and progestin hormones in users of Ortho Evra with those in a typical birth control pill. In general, increased estrogen exposure may increase the risk of blood clots. However, it is not known whether women using Ortho Evra are at a greater risk of experiencing these serious adverse events.
 
Lieff Cabraser Heimann & Bernstein, LLP represents persons injured in vehicle accidents. Click here to submit your case.
Our lawyers have years of experience successfully representing clients in personal injury cases.
There is no charge or obligation for our review of your case.
In death and serious injury cases, we are pleased to visit you where you live, at no cost, to discuss your legal rights and answer your questions.
We have retained product safety and medical experts nationwide to assist our clients with their claims.
The new bolded warning specifically states that women who use Ortho Evra are exposed to about 60 percent more total estrogen in their blood than if they were taking a typical birth control pill containing 35 micrograms of estrogen. However, the maximal blood level of estrogen (peak blood levels) is about 25% lower with Ortho Evra than with typical birth control pills. While the estrogen level with the patch remains constant for one week until the patch is removed, the peak blood levels with a daily birth control pill rapidly declines to levels that are lower than on the Orthro Evra.
FDA is continuing to monitor safety reports for the Ortho Evra patch. The manufacturer, Ortho McNeil Pharmaceuticals is conducting additional studies to compare the risk of developing serious blood clots in women using Ortho Evra to the risk in women using typical birth control pills that contain 35 micrograms of estrogen.
The new labeling information is available along with additional information for healthcare providers and consumers online at www.fda.gov/cder/drug/infopage/orthoevra/default.htm.
     Trademark Notice: Personal Injury Lawyer America is an electronic newsletter from Lieff Cabraser Heimann & Bernstein, LLP. Lieff Cabraser represents clients in a wide range of cases, including personal injury and wrongful death lawsuits. Our personal injury attorneys | lawyers are committed to providing the very best representation and support possible for our clients. This website provides information on the legal rights of the injured and the latest news on product defects and related lawsuits.
     Lieff Cabraser is not affiliated in any way with any trademark owner. The use of any trademarks on this site is for product identification and information purposes only.
     About Lieff Cabraser: We have offices in San Francisco, New York and Nashville. Our lawyers have represented clients in personal injury, wrongful death and rollover crashes and product defect lawsuits across America, including residents of Alaska, Alabama, Arkansas, Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Maryland, Maine, Michigan, Minnesota, Missouri, Montana, North Carolina, North Dakota, Nebraska, New Hampshire, New Jersey, New Mexico, Nevada, New York, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Dakota, Tennessee, Texas, Utah, Virginia, Vermont, Washington, Wisconsin, West Virginia and Wyoming.
     Among the cases our personal injury attorneys are prosecuting are the Medtronic heart lead recall, the AMO contact lens solution recall, the Peter Pan peanut butter recall, Guidant pacemaker defects, SUV rollover accidents, popcorn workers lung injuries, and Ford switch fires.
     Disclaimer: The hiring of legal professionals is an important decision that should not be based on advertising alone. Please read our disclaimer.
Copyright © 2008 Lieff Cabraser Heimann & Bernstein, LLP

Read our Personal Injury Law brochure